Lack of Associations among Cancer and Albumin Adducts, ras p21 Oncoprotein Levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a Nested Case-Control Study of Lung Cancer within the Physicians' Health Study
Open Access
- 1 July 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (7) , 1417-1419
Abstract
There was a priori evidence that PAH-albumin adducts and ras p21 of the biomarkers were biologically relevant, but their predictive ability had not been evaluated in a prospective design. For example, studies have shown that certain protein adducts, including PAH-albumin adducts, are correlated with the corresponding DNA adducts and might serve as feasible surrogates (2). However, the half-lives of the two biomarkers vary, and, unlike DNA adducts, protein adducts do not reflect interindividual variability in DNA repair. The ras oncogene has been shown to be activated by mutagens and clastogens. Moreover, ras mutation and/or overexpression has been directly implicated in the development of lung tumors (3-9). We also examined the contribution of polymorphisms in genes controlling metabolic activation and detoxification pathways for carcinogens that mediate the initial steps in environmental carcinogenesis (10). Genetic polymorphisms in the selected genes have been previously implicated in at least one study of lung cancer, although results have not been consistent (11-13).Keywords
This publication has 24 references indexed in Scilit:
- CYP1A1andCYP2D6polymorphism and risk of lung cancer in a North Indian populationBiomarkers, 2003
- Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibilityPharmacogenetics, 2001
- Expression of xenobiotic-metabolizing CYPs in human pulmonary tissueExperimental and Toxicologic Pathology, 1999
- SHORT COMMUNICATION: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-AmericansCarcinogenesis, 1993
- Role of genetics and drug metabolism in human cancer riskMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1991
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990
- Methodologic considerations in the design and conduct of randomized trials: the U.S. Physicians' Health StudyControlled Clinical Trials, 1989
- Oncogenes, Growth Factors, and Signal TransductionNew England Journal of Medicine, 1989
- Finding the Anti-OncogeneScientific American, 1988
- Mutational Activation of the K-rasOncogeneNew England Journal of Medicine, 1987